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Null Mutations Lacking Substance: Minireview
Elucidating Pain Mechanisms
by Genetic Pharmacology
and Krause, 1990), and the development of high affinity
nonpeptide specific neurokinin receptor antagonists
(Snider et al., 1991), represented major breakthroughs.
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Clifford J. Woolf, Richard J. Mannion,
and Simona Neumann
Neural Plasticity Research Group
Department of Anesthesia and Critical Care
Massachusetts General Hospital
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the periphery to the central nervous system. This infor-Charlestown Navy Yard
mation is carried by two types of fibers; unmyelinatedCharlestown, Massachusetts 02129
C-fibers, which are nociceptors and thermoreceptors,
and myelinated A-fibers, which are a combination of
Elucidating the function of particular neurotransmitters
low threshold mechanoreceptors and high threshold
and their receptors has traditionally relied upon pharma- mechano- and thermoreceptors. Although modality-
cological approaches using compounds that act as spe- specific sensory neurons exist, no modality-specific
cific agonists or antagonists at defined receptors on the
chemical phenotype has been discovered. Substance
pre- and postsynaptic membrane. A recent tool has been
P immunoreactivity is found in z20% of lumbar dorsal
added to thearmamentarium for studying synaptic func- root ganglia (DRG) neurons, almost all of which are small
tion: genetic manipulations, particularly null mutations neurons that also express the nerve growth factor (NGF)
or ªknockoutsº that delete specific ligands or their re- receptor TrkA. Substance P is shipped from the cell
ceptors. It is appropriate, though, to ask what the genetic bodies of DRG neurons into their peripheral and central
approach adds to the information that can begleaned by terminals. We will first discuss the actions of substance
classic synaptic pharmacology, and to consider whether P in the periphery, and then centrally, in the spinal cord.
ªgenetic pharmacologyº can unambiguously define the Substance P in Neurogenic Inflammation
overall function of an individual transmitter/neuromodu- When peripheral terminals are depolarized by appro-
lator in complex neurobiological systems. The neuro- priate mechanical, thermal, or chemical stimuli, sub-
peptide substance P and its receptor NK1 are worth stance P, along with calcitonin gene-related peptide
examining in this context, since mice with targeted mu- (CGRP), is released and acts on postcapillary venules
tations deleting the preprotachykinin gene that pro- to produce increased permeability (substance P) and
duces substance P and neurokinin A (Zimmer et al., dilatation (CGRP), a phenomenon known as neurogenic
1998; Cao et al., 1998) and the substance P receptor NK1 inflammation. The increased permeability produced by
(De Felipe et al., 1998) have recently been generated. substance P is associated with an extravasation of
In 1977, Tom Jessell and Les Iversen proposed an plasma proteins from the intravascular to the extracellu-
intriguing model for synaptic transmission from high lar compartment and is uniformly reduced by NK1 recep-
threshold nociceptive primary sensory neurons (C-fibers) tor antagonists. The functional significance of neuro-
to second-order neurons in the spinal cord, where the genic extravasation has been hotly debated; a role for
release of substance P, acting as a primary afferent it has beensuggested in migraine, asthma, gastrointesti-
transmitter, was regulated by opioids. Do the pharmaco- nal inflammatory disease, and rheumatoid arthritis.
logical and genetic tools now available answer the ques- Substance P in the Spinal Cord: C-Fiber
tion that has dominated the field since the publication Synaptic Transmission
of the Jessell and Iversen model: is substance P the C-fiber central terminals in the superficial dorsal horn
pain transmitter? To determine this,we first review some (laminae I and II) contain substance P and other peptides
key features of substance P and its pharmacology be- in dense core vesicles and glutamate. The NK1 receptor
fore comparing the phenotype of the NK1 and pre-pre- is expressed by cells in lamina I and the deeper laminae
protachykinin A (tachykinin 1) knockout mice. of the dorsal horn but not in lamina II, the site of maximal
Tachykinins and Their Receptors substance P innervation. However, NK1-expressing cells
Substance P, NKA, and NKB are members of the tachy- in the deeper laminae extend dendrites up into the su-
kinin small peptide family, allof which share the C-terminal perficial dorsal horn, where internalization of NK1 recep-
sequence Phe±X±Gly±Leu±Met±NH2. Substance P and tors on binding substance P can be observed (Mantyh
NKA are both encoded by the preprotachykinin-A gene et al., 1995).
(PPT-A/tac 1) and are produced through alternative Substance P is released in the dorsal horn by periph-
splicing of three different RNA transcripts. Neurokinin eral C-fiber activation, apparently requiring greaterstim-
B, the other major member of the tachykinin family, is ulation intensities than those that release glutamate. The
encoded by the PPT-B/tac 2 gene. Three seven trans- neuropeptide depolarizes dorsal horn neurons in vivo
membrane G protein±coupled molecules form the tachy- and in vitro, largely by blocking potassium currents.
kinin receptors, NK1, NK2, and NK3, with maximal af- C-fibers evoke both fast and slow synaptic currents in
finity for substance P, NKA, and NKB, respectively. spinal neurons, and on the basis of work in isolated
Considerable effort has been devoted to studying the neonatal spinal cord preparations, it looked for a while
distribution of substance P in different neuronal popula- as if substance P alone was responsible for the slow
tions, and its neuropharmacology has been extensively synaptic current. However, it is now clear that the C-fiber±
investigated (reviewed by Regoli et al., 1994). The clon- evoked slow current is a complex event produced by
corelease of a number of transmitters acting on multipleing of the NK1 receptor (Yokota et al., 1989; Hershey
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and Huang, 1992). The NMDAreceptor can also bephos-
phorylated on its tyrosine residues via src (Yu et al.,
1997) or the brain-derived neurotrophic factor (BDNF)
receptor/tyrosine kinase TrkB (Suen et al., 1997; Figure
1), resulting in a change in channel open time and clus-
tering. BDNF, interestingly, is present in dense core vesi-
cles in substance P±expressing (TrkA-positive) C-fibers,
and its receptor TrkB is present on dorsal horn neurons.
Posttranslational changes in the NMDA receptor,
by increasing glutamate sensitivity, will boost the re-
sponses of spinal neurons to any subsequent gluta-
matergic inputÐthe phenomenon of central sensitiza-
tion. Central sensitization is responsible for several key
elements of postinjury pain hypersensitivity, including
the spread of abnormal sensitivity beyond the site of
injury (secondary hyperalgesia) and the generation of
pain by normally low threshold mechanoreceptors (allo-
dynia) (Woolf, 1983). The capacity of substance P to
modify glutamate sensitivity may represent one of its
prime actions, acting as a synaptic power-booster or
turbocharger and thereby contributing to the initiation
of central sensitization.
NK1 receptor antagonists reduce the development of
central sensitization induced by electrical stimulation or
chemical activation of C-fibers by irritants like mustard
oil, capsaicin, or formalin. Substance P can transfer in-
put from C-fibers to dorsal horn neurons by producing
postsynaptic depolarizations. It is not essential, how-
ever, because of the multiple parallel transmitters/
receptors involved in C-fiber synaptic transmission. In
Figure 1. C-Fiber Transmission and Sensitization the same way, the neuropeptide may be sufficient but
(A) A representation of the synaptic contact made between the not necessary for the induction of central sensitization.
central terminals of C-fibers and dorsal horn neurons in the spinal Substance P and Inflammatory Hypersensitivity
cord. The terminal contains multiple neurotransmitters and neuro-
Peripheral inflammation results in an upregulation ofmodulators, the release of which is controlled by numerous presyn-
NGF levels in the inflamed tissue, which has beenaptic receptors. The postsynaptic membrane contains several me-
shown, using neutralizing antisera and TrkA±Fc fusiontabotropic, ionotropic, and tyrosine kinase receptors that contribute
to excitation as well as inhibitory receptors. proteins, to be linked to inflammatory pain hypersensi-
(B) In addition to generating inward currents in the postsynaptic tivity both by a direct action on the peripheral terminals
neuron, C-fiber inputs initiate long-lasting alterations in the excitabil- of nociceptors and by altering the phenotype of sensory
ity as a result of the phosphorylation of the NMDA receptor.
neurons following retrograde transport of the NGF to the
DRG. Acute inflammation results in an NGF-dependent
ionotropic and metabotropic receptors on the postsyn- increase in the numbers of cells expressing PPT-A
aptic membrane (Figure 1). In addition to substance P, mRNA in the DRG. After inflammation, substance P be-
there is an NMDA and mGluR component to the slow gins to be expressed in a subpopulation of DRG neurons
synaptic current. NK1 antagonists reduce but do not with myelinated A-fibers that acquire some functional
eliminate slow potentials evoked by C-fiber inputs. The properties normally associated only with C-fibers (Neu-
C-fiber±evoked slow synaptic potential offers the oppor- mann et al., 1996)Ðthe generation of action potential
tunity for considerable temporal summation, and indeed after-discharge and induction of c-fos in dorsal horn
such a use-dependent increase in C-fiber±evoked ac- neurons and production of progressive hypersensitivity
tion potential discharge, termed windup by its discov- in response to intermittent tactile stimulation. In keeping
erer Lorne Mendell, does occur and is sensitive both to with the suggestion that the elevation in substance P
NMDA and to NK1 antagonists. There is also complex sig- induced by inflammation contributes to pain hypersensi-
naling on the presynaptic C-fiber terminal (see Figure 1). tivity, increased NK1 receptor internalization on den-
Substance P and Central Sensitization drites of cells in the dorsal horn in response to noxious
While glutamate appears to be able to promote sub- stimuli, and novel responses to previously innocuous
stance P release via presynaptic NMDA autoreceptors stimuli, have been observed (Abbadie et al., 1997), as
(Liu et al., 1997), substance P can potentiate the action of has upregulation of the NK1 receptor by dorsal horn
glutamate on postsynaptic NMDA receptors, a complex neurons in inflammatory models (Krause et al., 1995).
reciprocal interaction, enhancing synaptic efficacy (Fig- In general, NK1 receptor antagonists reduce inflam-
ure 1). PKC-mediate phosphorylation of the NMDA recep- matory pain hypersensitivity in various different animal
tor partially relieves the voltage-dependent Mg21 block, models without affecting the normal responsiveness to
which in turn enables glutamate to generate a greater noxious stimuli. Unfortunately, less success has been
achieved in clinical trials. This is partly because someinward current through the NMDA ion channel (Chen
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Table 1. Tachykinins and Pain: the Effects of the Knockouts and Pharmacology
PPT-A/Tac1 KO PPT-A/Tac1 KO NK1 KO NK1 Antagonists
(Zimmer) (Basbaum) (Hunt) (Subataxic Doses)
Thermal
Tail Flick 1 1 1
Hot Plate* 2 @ 528C 1 @ 52.58C and 58.58C 1 1
Mechanical 2 @ 55.58C
NOCICEPTION Von Frey Threshold 1 11
Chemical
Acetic Acid Writhing* 1 2 1 2
Formalin: Early Phase* 22 1 1 122
(20 ml, 5%) (10 ml, 1.2%) (0.6 and 2%) (25 ml, 2%)
CENTRAL Formalin: Late Phase* 2 2 21
SENSITIZATION (20 ml, 5%) (10 ml, 2%) (25 ml, 2%)
INFLAMMATORY Mechanical 1 1 2
HYPERALGESIA
MISCELLANEOUS Stress-Induced Analgesia* 1 2 2
Neurogenic Extravasation 2 2 2
*Apparent discrepancy; 1, normal; 2, reduced; 22, abolished; blank, not tested.
of these drugs have nonspecific actions, particularly on a number of changes consistent with results using NK1
calcium channels, and because of limited brain pene- and NK2 antagonists were observedÐneurogenic in-
trance after systemic administration and variable bio- flammation was significantly abolished, and mechanical
availability after oral administration. In humans, NK1 an- sensitivity was comparable to the wild-type animals
tagonists have been reported to have no effect on (with the exception of very high intensity of stimulation
migraine, little or no effect on dental postoperative pain, in the Basbaum PPT-A knockout, which showed de-
no effect on windup in human volunteers, and no effect creased sensitivity). Surprisingly, no changes in me-
on patients with osteoarthritis. chanical hypersensitivity induced by inflammation were
Measuring Pain seen in the NK1 and PPT-A knockout animals.
Pain-related behavior can be tested in several different In their PPT-A knockout, Basbaum and colleagues
ways. The reaction to high intensity potentially tissue- found behavioral changes that they interpreted as indi-
damaging (noxious) stimuli can be investigated using cating an intensity-coding role for substance P. At low
mechanical, thermal, or chemical stimuli applied to skin, intensity noxious stimulation, independent of modality,
deep tissue, or viscera. Central sensitization in turn man- the mutants and wild types behaved the same; only at
ifests as a hypersensitivity to peripheral stimuli following stimulation intensities producing moderate to severe
the activation of C-fiber nociceptors. The formalin test, pain was the phenotype manifest, with no differences
for example, has an immediate ªearlyº phase that mea- observed at very high stimulation intensities. Although
sures the direct response to the irritant (nociceptive
this does not match findings in mice using NK1 and NK2
pain) and a ªlateº phase presenting after about 10 min-
antagonists (e.g., Seguin et al., 1995), it is consistent
utes that reflects changes in the excitability of neurons
with the fact that greater stimulation intensities arein the spinal cord (central sensitization). The acetic acid
required for substance P release than for glutamate re-writhing test, in contrast, is a test only of visceral noci-
lease from C-fibers. Where the data becomes more dif-ceptive chemosensitivity. Inflammatory pain, which can
ficult to evaluate is the analysis of central sensitizationÐbe tested by producing localized inflammation, has two
both Zimmer (PPT-A) and Hunt (NK1), consistent withcomponentsÐallodynia, the pain produced by normally
the pharmacology, found a reduced second phase ofinnocuous stimuli, and hyperalgesia, an increased re-
the formalin test (central sensitization), but this was nor-sponse to noxious stimuli. These take several hours to
mal in the Basbaum PPT-A knockout.manifest.
Other inconsistencies between the null mutationsKnocking out Substance P and the NK1 Receptor
were also striking. The Zimmer PPT-A knockout showedGiven the substantial information available on substance
normal acetic acid writhing, whereas writhing was re-P pharmacology, certain expectations can be made about
duced in the Basbaum PPT-A knockout. A reduced re-the likely phenotype of mice lacking either substance P
sponse in the hotplate test at 528C found in the Zimmer(Basbaum and Zimmer) or the NK1 receptor (Hunt): a
PPT-A knockoutwas not observed at the same tempera-lack of neurogenic extravasation, minimal effect on
ture for the Basbaum PPT-A knockout. The NK1 knock-baseline nociceptive sensitivity, reduced central sensiti-
out showed a reduced stress-induced analgesia, whichzation, and diminished inflammatory hyperalgesia. De-
was not observed in the Zimmer PPT-A knockout.spite the fact that ligand knockouts cannot be compared
Although the phenotypes of the different knockoutsdirectly with receptor knockouts, particularly since the
clearly point to an involvement of substance P in pain,PPT-A knockouts eliminate both substance P and NKA,
there is no simple explanation for the apparently incon-which act onNK1 and NK2 receptors, respectively, some
sistent behavioral responses of the different animals.commonality might be anticipated between the animals.
The knockout approach is susceptible to a number ofAll three knockouts appeared healthy, were fertile,
and showed altered pain behavior. As Table 1 illustrates, problems related to the genetic background of the mice
Neuron
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(Banbury Conference on Genetic Background in Mice, genetically and pharmacologically using protocols de-
signed to evaluate opiate or nonsteroidal anti-inflamma-1997), the developmental actions of the deleted gene,
tory type analgesics and not in studies where pain hy-and redundancy of function and compensatory changes,
persensitivity after inflammation is a prominent feature.as well as the sensitivity, specificity, and reproducibility
However, despite the fact that available clinical trial dataof the behavioral tests used to measure the phenotype
are not encouraging, itmay be premature to totally aban-of the animals. All of these may contribute here. For
don NK1 receptor antagonists for pain treatment. Sinceinstance, there is a growing appreciation of the enor-
C-fiber input to the CNS involves parallel transmittermous strain differences in the response of mice to nox-
action on multiple receptors, a polypharmacy approachious stimuli and analgesic drugs. C57BL/6 mice are,
might make more sense if one is targeting postsynapticfor example, very resistant to the analgesic actions of
receptors. This could involve combinations of NK1,morphine. The Basbaum PPT-A knockout was created
mGluR, and NMDA receptor antagonists together withfrom a different strain than the Zimmer PPT-A and the
opioids to improve analgesic efficacy.Hunt NK1 knockouts; the mice have not been back-
It is possible that substance P may be involved onlycrossed to a point where genetic stability is present,
in severe pain, being released in the spinal cord byand as a consequence the diverse hybrid genetic back-
massive amounts of tissue damage. Alternatively, sub-ground of each animal raises the possibility that differ-
stance P may play a nonessential role in the pathophysi-ences in modifier genes may alter the phenotype inde-
ology of pain, such that eliminating its action does notpendently of the mutation. It is likely that the differences
eliminate pain. Rather than signaling the presence orin strains are responsible for someof the inconsistencies
absence of noxious stimuli, it is possible that substancein the behavioral testsÐthere are larger differences be-
P, acting in parallel rather than serial synaptic informa-tween the reaction times to a standard nociceptive test
tion transfer, contributes to synaptic gain more than(hotplate at 528C) between Hunt wild-type mice and Zim-
pain and that its action is more one of modulation thanmer and Basbaum wild types than with the gene dele-
transmission.tions. The Basbaum wild-type mice generated .30 ab-
dominal stretches with acetic acid, whereas Zimmer
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